Board-reviewed guide covering daily fiber targets by age and sex, the difference between soluble and insoluble fiber, blood sugar effects, and practical food sources with serving sizes.
GLP-1 weight trials report total body weight, not muscle. See what resistance training, protein, leucine and creatine research does and does not show.
A complete guide to PCOS diagnosis: which blood tests, imaging, and clinical criteria doctors use, what normal and abnormal results mean, and how to prepare for each step.
Glimepiride is an oral sulfonylurea for type 2 diabetes that boosts insulin release, lowering A1C by 1 to 2 points but risking hypoglycemia.
Sudden, constant hunger in your 40s or 50s is often tied to perimenopause-driven hormone shifts. Learn the biology, the red flags, and what the evidence actually supports.
A clinically detailed explanation of why menopause causes weight gain, covering estrogen loss, metabolic slowdown, cortisol, sleep, and evidence-based treatments including HRT and GLP-1 agonists.
After menopause, estrogen loss redirects fat storage into the abdomen, where it is linked to inflammation, insulin resistance, and cardiovascular risk. This article explains the mechanisms, distinguishes established evidence from areas needing verification, and outlines what a reader can realistically act on.
Processed foods disrupt gut microbiome diversity, trigger chronic low-grade inflammation, and hijack appetite-regulating hormones. Learn the specific mechanisms, the clinical evidence, and what dietary changes actually move the needle.
PCOS runs in families, but the inheritance pattern is complex. Learn what genetic research, twin studies, and candidate gene data tell us about your family risk and what to do about it.
A guide to the best fiber supplements for menopausal women, covering types, doses, clinical evidence, and how fiber affects blood sugar, weight, and cardiovascular risk during the menopause transition.
A complete guide to Cigna coverage for Trulicity (dulaglutide), including formulary tier, prior authorization criteria, step therapy requirements, denial appeals, and manufacturer savings options.
A guide to dulaglutide (Trulicity) overdose: symptoms, mechanisms, treatment protocols, and when to seek emergency care.
A guide to dutasteride (Avodart) safety in adults aged 30, 49, covering sexual side effects, cardiovascular signals, cancer risk, drug interactions, and how to weigh risks against benefits for BPH and hair loss.
Does dutasteride (Avodart) change appetite or food cravings? A deep dive into the pharmacology, clinical trial data, and patient reports around dutasteride and appetite.
The Avodart label reports cardiac failure rates in REDUCE and CombAT, calls their significance unknown, and notes heart-drug interactions.
Find out whether Cigna covers Avodart (dutasteride) for BPH and hair loss, what prior-authorization criteria apply, how step therapy works, and how to appeal a denial.
A clinical guide to dutasteride (Avodart) monitoring in adults 65 and older, covering falls risk, renal considerations, drug interactions, PSA interpretation, and deprescribing thresholds.
A deep dive into dutasteride (Avodart) and its effects on mood, depression, anxiety, libido, and cognitive function, with primary-literature citations and clinical guidance.
A clinician-level review of dutasteride (Avodart) and muscle preservation strategies, covering DHT suppression, resistance training protocols, protein targets, and monitoring guidance backed by primary-source evidence.
A guide to dutasteride (Avodart) monitoring protocols for men and women aged 50 to 64, covering PSA interpretation, cardiovascular checks, hormone interactions, and safety labs at each follow-up visit.
What happens when you stop dutasteride during illness, when it's safe to restart, and exactly how to resume therapy after acute illness. guidance with primary-literature citations.
Board-reviewed guide on the dutasteride (Avodart) pre-surgery hold window: when to stop, why it matters for PSA, bleeding, and anesthesia, and how to safely restart.
A clinician-level review of dutasteride (Avodart) dosing in renal impairment, covering pharmacokinetics, mechanism of action, trial data, and practical prescribing guidance.
The Avodart label lists no insomnia among common reactions and no effect on sleep stages. It also covers mood data from the label and a register study.
Everything clinicians and patients need to know about switching between dutasteride, finasteride, and other 5-alpha-reductase inhibitors, with trial evidence, dosing protocols, and pharmacokinetic rationale.
A guide to dutasteride (Avodart) monitoring for men aged 18 to 29, covering labs, fertility, sexual side effects, PSA interpretation, and when to stop treatment.
A guide to dutasteride safety in young adults ages 18, 29, covering sexual side effects, fertility, mental health signals, contraindications, and monitoring protocols with primary-source citations.
Does Jardiance (empagliflozin) affect bone density or fracture risk? A review of the clinical trial data, mechanisms, and monitoring guidance for patients and prescribers.
When and how to safely restart empagliflozin after illness, surgery, or hospitalization. Covers sick-day rules, DKA risk, renal thresholds, and a step-by-step restart protocol backed by primary literature.
Does enclomiphene citrate change appetite or cravings? A clinician-level review of the mechanisms, clinical trial data, and practical guidance for men on enclomiphene therapy.
A physician-level review of the cancer risk signals associated with enclomiphene citrate, covering estrogen receptor pharmacology, published trial safety data, and how clinicians should counsel patients on off-label use for secondary hypogonadism.
A guide to enclomiphene citrate dosing in men aged 65 and older, covering starting doses, titration, renal and hepatic adjustments, fall risk, drug interactions, and monitoring protocols for secondary hypogonadism.
A deep dive into how enclomiphene citrate affects testosterone, metabolic rate, body composition, and energy expenditure, with primary-literature citations and clinical dosing guidance.
A physician-level guide to safely restarting enclomiphene citrate after acute illness, covering when to pause, how to re-titrate, and what lab values guide the decision.
A deep dive into how enclomiphene citrate affects sleep architecture, REM sleep, slow-wave sleep, and testosterone-driven circadian signaling in men with secondary hypogonadism.
A physician-level review of epitalon tetrapeptide's long-term cardiovascular effects, covering telomerase biology, oxidative stress, lipid profiles, and what Russian cohort data and preclinical trials reveal about heart health outcomes.
What FDA found on epitalon safety for adults aged 50 to 64, including the cancer and immunogenicity concerns and the limited human studies.
What FDA's 2026 review and human studies show about epitalon and sleep, and why a urinary melatonin marker is not evidence of better sleep.
A clinician-level guide to switching protocols for epitalon tetrapeptide, covering mechanism, class comparisons, dosing cycles, and evidence-based transition strategies with primary-source citations.
No validated lab panel or monitoring schedule exists for epitalon in adults aged 18-29. See what FDA found on human studies and safety.
A clinical review of epitalon tetrapeptide safety in adults aged 18, 29, covering telomere biology, known risks, dosing considerations, fertility implications, and what current evidence does and does not support.
A review of oral estradiol cancer risk signals across breast, endometrial, ovarian, and other cancers, distinguishing WHI trial data from guideline statements and noting where citation verification is still required.
A guide to oral estradiol safety in geriatric patients (65+), covering cardiovascular risk, VTE, breast cancer data, drug interactions, and deprescribing thresholds.
A guide to oral estradiol missed-dose management, covering pharmacokinetics, step-by-step recovery instructions, symptom implications, and the clinical evidence behind current recommendations.
A clinician-level guide to diagnosing and correcting oral estradiol plateau and non-response in menopausal HRT, covering pharmacokinetics, lab interpretation, dose adjustments, and route-switching strategies with primary literature citations.
A clinician-level guide to the oral estradiol pre-surgery hold window: timing, thrombotic risk mechanisms, guideline recommendations, and safe restart protocols after surgery.
A deep dive into how oral estradiol affects libido, arousal, lubrication, and pain during sex, with primary-literature citations, real doses, and a clinical decision framework.
A clinician-level review of how oral estradiol affects sleep architecture, REM duration, slow-wave sleep, and sleep efficiency in menopausal women, with primary-literature citations and dosing context.
A complete guide to TRICARE coverage, formulary tier, prior authorization, step therapy, and appeal pathways for oral estradiol (estrace, generic 17-beta estradiol) for menopausal vasomotor symptoms.
A clinician-level review of how oral estradiol affects hair growth, hair loss, skin thickness, collagen, sebum, and wound healing, with primary-literature citations and practical dosing context.
A guide to estradiol transdermal patch safety for adults aged 30 to 49, covering cardiovascular risk, breast cancer data, clot risk, contraindications, and monitoring protocols.
A clinician-level review of estradiol transdermal patch use in patients with autoimmune conditions, covering disease-specific risks, benefits, dosing, and monitoring protocols backed by primary literature.
What long-term transdermal estradiol use appears to do to cardiovascular risk, how that differs from oral estrogen data, and where the evidence for the patch specifically is still incomplete.
A clinician-level review of how transdermal estradiol affects memory, processing speed, and dementia risk in peri- and postmenopausal women, framed around what is established, what is plausible, and what remains unproven.
A clinician-level comparison of compounded and FDA-approved branded estradiol transdermal patches covering bioequivalence, safety data, regulatory status, cost, and how to choose the right formulation for menopausal hormone therapy.
Evidence-based guide to estradiol transdermal patch dosing for adults ages 50 to 64, including starting doses, titration schedules, cardiovascular risk stratification, and monitoring protocols prepared by the HealthRX.com Editorial Team.
A clinician-level review of estradiol patch pharmacokinetics covering absorption, distribution, metabolism, and excretion, with cited trial data, dose-exposure relationships, and practical prescribing implications.
A clinician-level guide to how heat, cold, humidity, and UV exposure affect estradiol transdermal patch adhesion, absorption, and dosing across seasons. Includes primary-literature citations, dosing guidance, and storage recommendations.
A detailed guide to UnitedHealthcare coverage for estradiol transdermal patches, including formulary tiers, prior authorization criteria, step therapy requirements, and how to appeal a denial.
A guide to estradiol transdermal patch dosing for women aged 18 to 29, covering starting doses, titration, the evidence base for this age group, and how patch therapy interacts with fertility and family planning goals.